Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional hemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation
McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, R Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T
Record ID 32009100023
English
Authors' recommendations:
Study found that, in the short term, there is little clinical difference between deferasirox, deferoxamine and deferiprone in terms of removing iron from the blood and liver, and that deferasirox may be cost-effective compared with deferoxamine in patients with beta-thalassaemia and sickle cell disease but is unlikely to be cost-effective compared with deferiprone.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/1632
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Chronic Disease
- Cost-Benefit Analysis
- Drug Therapy, Combination
- Randomized Controlled Trials as Topic
- Technology Assessment, Biomedical
- Treatment Outcome
- Anemia
- Blood Transfusion
- Deferoxamine
- Hemosiderosis
- Iron Chelating Agents
- Pyridones
- Triazoles
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.